

# Charles J Diskin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3067436/publications.pdf>

Version: 2024-02-01

58  
papers

778  
citations

516710

16  
h-index

552781

26  
g-index

58  
all docs

58  
docs citations

58  
times ranked

744  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Long-Term Clinical Course of Systemic Lupus Erythematosus in End-Stage Renal Disease. <i>New England Journal of Medicine</i> , 1983, 308, 186-190.	27.0	164
2	Pharmacologic Intervention to Prevent Hemodialysis Vascular Access Thrombosis. <i>Nephron</i> , 1993, 64, 1-26.	1.8	44
3	Can acidosis and hyperphosphataemia result in increased erythropoietin dosing in haemodialysis patients?. <i>Nephrology</i> , 2006, 11, 394-399.	1.6	39
4	Towards an understanding of oedema. <i>BMJ: British Medical Journal</i> , 1999, 318, 1610-1613.	2.3	37
5	Effect of phosphate binders upon TSH and l-thyroxine dose in patients on thyroid replacement. <i>International Urology and Nephrology</i> , 2007, 39, 599-602.	1.4	33
6	A Hypothesis: Can Erythropoietin Administration Affect the Severity of Retinopathy in Diabetic Patients With Renal Failure?. <i>American Journal of the Medical Sciences</i> , 2007, 334, 260-264.	1.1	27
7	Is Systemic Heparin a Risk Factor for Catheter-Related Sepsis in Dialysis Patients?. <i>Nephron Clinical Practice</i> , 2007, 107, c128-c132.	2.3	27
8	The Comparative Benefits of the Fractional Excretion of Urea and Sodium in Various Azotemic Oliguric States. <i>Nephron Clinical Practice</i> , 2010, 114, c145-c150.	2.3	26
9	Creatinine and glomerular filtration rate: evolution of an accommodation. <i>Annals of Clinical Biochemistry</i> , 2007, 44, 16-19.	1.6	25
10	Acute Renal Failure Due to a Primary Renal B-Cell Lymphoma. <i>American Journal of Kidney Diseases</i> , 2007, 50, 885-889.	1.9	25
11	An Analysis of the Effect of Routine Medications on Hemodialysis Vascular Access Survival. <i>Nephron</i> , 1998, 78, 365-368.	1.8	24
12	Understanding the pathophysiology of hemodialysis access problems as a prelude to developing innovative therapies. <i>Nature Clinical Practice Nephrology</i> , 2008, 4, 628-638.	2.0	24
13	Novel Insights into the Pathobiology of the Vascular Access – Do They Translate into Improved Care?. <i>Blood Purification</i> , 2010, 29, 216-229.	1.8	24
14	Removal of Methotrexate by Peritoneal Dialysis and Hemodialysis in a Single Patient with End-Stage Renal Disease. <i>American Journal of the Medical Sciences</i> , 2006, 332, 156-158.	1.1	23
15	Beyond Anemia: The Clinical Impact of the Physiologic Effects of Erythropoietin. <i>Seminars in Dialysis</i> , 2008, 21, 447-454.	1.3	21
16	Toward the optimal clinical use of the fraction excretion of solutes in oliguric azotemia. <i>Renal Failure</i> , 2010, 32, 1245-1254.	2.1	18
17	The prevalence and meaning of eosinophilia in renal diseases on a nephrology consultation service. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2549-2558.	0.7	17
18	Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker?. <i>Journal of Nephrology</i> , 2007, 20, 410-6.	2.0	15

#	ARTICLE	IF	CITATIONS
19	Antimicrobial Activity in Continuous Ambulatory Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 1983, 3, 150-154.	2.3	12
20	Creatinine and GFR: an imperfect marriage of convenience. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3338-3339.	0.7	11
21	Doxycycline may reduce the incidence of aneurysms in haemodialysis vascular accesses. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 959-961.	0.7	10
22	Recurrent metabolic alkalosis and elevated troponins after crack cocaine use in a hemodialysis patient. <i>Clinical and Experimental Nephrology</i> , 2006, 10, 156-158.	1.6	10
23	Efficacy of an Attachable Silver Impregnated Subcutaneous Cuff for the Prevention of Catheter-Associated Infections in Patients on Chronic Maintenance Hemodialysis. <i>Nephron</i> , 1995, 69, 357-359.	1.8	9
24	Heparin and Biofilm: Is this the Risk Factor for Catheter-Related Sepsis?. <i>American Journal of Kidney Diseases</i> , 2008, 52, 197-198.	1.9	8
25	Recurrent Hyponatremia after Intrathecal Methotrexate not Related to Antidiuretic Hormone: Is a Natriuretic Peptide Activated?. <i>American Journal of the Medical Sciences</i> , 2006, 331, 37-39.	1.1	7
26	The first fistula: influence of location on catheter use and the influence of catheter use on maturation. <i>International Urology and Nephrology</i> , 2015, 47, 1571-1575.	1.4	7
27	Diagnosis of tuberous sclerosis in a patient who presented with polycystic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 547-548.	0.7	6
28	Malignancy-Related Hypercalcemia Developing on a Bisphosphonate but Responding to Calcitonin. <i>Clinical Lung Cancer</i> , 2007, 8, 434-435.	2.6	6
29	Heparin, biofilm, and catheter-related sepsis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 61, 80.	1.8	6
30	The clinical significance of aldosterone in ESRD: Part II. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1331-1332.	0.7	5
31	Observe and be guarded: the development and rupture of an abdominal aortic mycotic aneurysm in an afebrile hemodialysis patient with normal angiogram, and CT scan, and sterile blood cultures. <i>Clinical and Experimental Nephrology</i> , 2004, 8, 388-391.	1.6	5
32	Catheter locks, heparin and biofilm: what is this the risk?. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2708-2709.	0.7	5
33	Erythropoietin, haemoglobin, heart failure, and mortality. <i>European Heart Journal</i> , 2008, 29, 2695-2695.	2.2	5
34	Pharmacologic intervention to prevent hemodialysis vascular access thrombosis: The next generation of treatment?. <i>Kidney International</i> , 2005, 67, 2505.	5.2	4
35	Erythropoietin Levels and Androgens Use: What Is Their Relationship in the Correction of Anemia?. <i>Archives of Internal Medicine</i> , 2007, 167, 309.	3.8	4
36	The Evolution of the Fractional Excretion of Urea as a Diagnostic Tool in Oliguric States. <i>American Journal of Kidney Diseases</i> , 2008, 51, 869-870.	1.9	4

#	ARTICLE	IF	CITATIONS
37	How effective is rescue therapeutic plasma exchange in treatment of SARS-CoV-2?. Therapeutic Apheresis and Dialysis, 2022, , .	0.9	4
38	Peritoneal dialysis in patients with liver cirrhosis and/or ascites. Wiener Klinische Wochenschrift, 2006, 118, 435-436.	1.9	3
39	Notes on angiotensin inhibition and vascular access survival: time for randomized controlled trials. Nephrology Dialysis Transplantation, 2006, 21, 823-823.	0.7	3
40	Hemoglobin Targets versus Oxygen Delivery: Is It Time for a New Paradigm?. Blood Purification, 2007, 25, 280-280.	1.8	3
41	Hitting the Target But Missing the Goal? Hemoglobin Targets Versus Oxygen Delivery. American Journal of Kidney Diseases, 2007, 50, 344.	1.9	3
42	Gustatory sweating recurring on peritoneal dialysis but resolving during periods of hemodialysis. Hemodialysis International, 2008, 12, 230-232.	0.9	3
43	de Ketham revisited: a modern-day urine wheel. Medical Journal of Australia, 2008, 189, 658-659.	1.7	3
44	Looking backward: a review of the treatment of systemic lupus erythematosus in end-stage renal disease after a quarter of century. Nephrology Dialysis Transplantation, 2006, 21, 1739-1739.	0.7	2
45	Does the Hyperfiltration of Minoxidil Result in Increased Proteinuria and Loss of Renoprotection Conferred by Angiotensin Inhibition?. Kidney and Blood Pressure Research, 2006, 29, 54-59.	2.0	2
46	In Reply to "Acute Renal Failure Due to a Primary Renal B-Cell Lymphoma". American Journal of Kidney Diseases, 2008, 52, 808-809.	1.9	2
47	The Promise of Pentoxifylline and Interference With the Renin-Angiotensin System in Diabetic Nephropathy. American Journal of Kidney Diseases, 2009, 53, 355.	1.9	2
48	Lessons From Single Cell Organisms: Insights Into the Antimicrobial and Toxic Effects of Peritoneal Dialysate Bases. Therapeutic Apheresis and Dialysis, 2010, 14, 127-135.	0.9	2
49	Use of the Fractional Excretion of Urea in an Azotemic Nonoliguric State: Type 1 Cardiorenal Syndrome. Therapeutic Apheresis and Dialysis, 2018, 22, 319-324.	0.9	2
50	Mental Effects of Excess Parathyroid Hormone in Hemodialysis Patients: A Possible Role for Parathyroid 2 Hormone Receptor?. Therapeutic Apheresis and Dialysis, 2020, 24, 285-289.	0.9	2
51	The Contribution of Nutrition to the Protective Value of High Plasma Aldosterone Concentrations in Hemodialysis Patients. Hypertension Research, 2007, 30, 751.	2.7	1
52	Immunology and the Evaluation of Risk Factors for Development of Spontaneous Bacterial Peritonitis. Digestive Diseases and Sciences, 2008, 53, 1154-1155.	2.3	1
53	Can the combination of calcium and parathormone levels above k/dolq guidelines be used as a marker of adynamic bone disease in African Americans?. International Urology and Nephrology, 2011, 43, 1127-1132.	1.4	1
54	Towards Erythropoietin Equations That Estimate Oxygen Delivery rather than Static Hemoglobin Targets. Nephron Clinical Practice, 2012, 120, c48-c53.	2.3	1

#	ARTICLE	IF	CITATIONS
55	Membranous Glomerulopathy in Hypogammaglobulinemia. American Journal of the Medical Sciences, 2017, 353, 307-309.	1.1	1
56	A dialysis patient with blurred vision. CKJ: Clinical Kidney Journal, 2008, 1, 250-252.	2.9	0
57	The role of the nephrologist in the treatment of lupus nephritis. Nature Clinical Practice Nephrology, 2007, 3, E1-E1.	2.0	0
58	Can omeprazole reduce the incidence of hypercalcemia in dialysis patients using calcium containing phosphate binders?. Journal of Nephrology, 2010, 23, 438-43.	2.0	0